ASCO International Perspective | Professor Samuel R. Denmeade: Biomarkers for Bipolar Androgen Therapy in mCRPC

ASCO International Perspective | Professor Samuel R. Denmeade: Biomarkers for Bipolar Androgen Therapy in mCRPC

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded successfully. In a recent late-breaking abstract (LBA) report, Professor Samuel R. Denmeade from Johns Hopkins University School of Medicine shared the specific results of the TRANSFORMER trial. This randomized trial targeted abiraterone-pretreated metastatic castration-resistant prostate cancer (mCRPC) patients, aiming to identify blood biomarkers. "Oncology Frontier" had the opportunity to interview Professor Samuel R. Denmeade to highlight the potential benefits and future directions of bipolar androgen therapy (BAT), a new treatment approach.
Breaking Through – Promising Results from Phase I Study of KSD-101 Dendritic Cell Vaccine in Treating EBV-Positive Hematologic Malignancies

Breaking Through – Promising Results from Phase I Study of KSD-101 Dendritic Cell Vaccine in Treating EBV-Positive Hematologic Malignancies

Epstein-Barr virus (EBV) infection is widespread among adults, yet there is no standard treatment for EBV-positive hematologic malignancies, leading to poor patient outcomes. At the 29th Annual Meeting of the European Hematology Association (EHA), Professor Chunrui Li from Tongji Hospital of Huazhong University of Science and Technology presented the results of her team’s Phase I exploratory trial of the KSD-101 dendritic cell vaccine in treating EBV-related hematologic malignancies. This study brings new hope for treating these diseases. Oncology Frontier-Hematology Frontier interviewed Professor Li to delve into this innovative research and discuss the potential impact of KSD-101 on the future of hematologic malignancy treatment.
EHA 5-Minute Interview | Professor Minghui Duan: Latest Advances in Myelofibrosis Treatment

EHA 5-Minute Interview | Professor Minghui Duan: Latest Advances in Myelofibrosis Treatment

Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF). At the 29th European Hematology Association (EHA) Annual Meeting held in Madrid, Spain, from June 13 to 16, 2024, notable advancements were made in MPN research. Oncology Frontier-Hematology Frontier invited Professor Minghui Duan from the Department of Hematology, Peking Union Medical College Hospital, to introduce and provide an in-depth review of two significant studies on myelofibrosis treatment. We hope Professor Duan's insights will help us understand the research progress in this field and provide important references for future research and treatment.
Rare Cause of Splenic Infarction with Cholestasis-Related Liver Failure: A Case of Diffuse Large B-Cell Lymphoma

Rare Cause of Splenic Infarction with Cholestasis-Related Liver Failure: A Case of Diffuse Large B-Cell Lymphoma

To help clinical hepatologists broaden their horizons and enrich their practical experience, the Hepatology Digest journal has invited Professor Shanhong Tang's team from the Department of Gastroenterology at General Hospital of Western Theater Command to create the "Liver Challenging Cases" column. This column compiles classic cases encountered by Professor Tang’s team over years of clinical practice and will periodically include complex or rare cases from renowned academic journals. The focus is on elucidating diagnostic and therapeutic approaches for various liver diseases, providing valuable clinical insights for colleagues.
APACC On-site Report | Dr. Ye Zhang: “Pay it Forward” – A New Strategy to Increase STD Testing Rates

APACC On-site Report | Dr. Ye Zhang: “Pay it Forward” – A New Strategy to Increase STD Testing Rates

In the era of 5G, the consumption and entertainment habits of sexually active young people have changed significantly, including activities such as drinking coffee, shopping, watching movies, and taking selfies. It is essential to continuously explore and improve strategies for testing and preventing sexually transmitted diseases (STDs) that are tailored to the times and local conditions. At the recent 9th Asia Pacific AIDS & Co-infections Conference (APACC 2024), Dr. Ye Zhang from the Kirby Institute at the University of New South Wales, Australia, presented "Innovations in Implementation Strategies of Delivery Models," introducing the "Pay it Forward" strategy and sharing more insights in an interview with Infectious Diseases Frontier.
Dr. Brigitte Quenum: Breaking the “isolated island” model and integrating resources to address HIV prevention and control challenges in Asia and the Pacific

Dr. Brigitte Quenum: Breaking the “isolated island” model and integrating resources to address HIV prevention and control challenges in Asia and the Pacific

Recently, at the 9th Asia-Pacific AIDS& Co- Infections Conference 2024 (APACC 2024), Dr. Brigitte Quenum, UNAIDS Regional Office for Asia and the Pacific, delivered a speech entitled "Challenges & Success in the Region" and in an interview with Infectious Disease Frontier,she introduced the challenges and solutions of HIV/AIDS prevention and treatment in the Asia- Pacific region, with particular emphasis on breaking the "isolated island" model of government or community fighting alone and achieving the integration of multiple resources.
Professor Jun Cheng: New Strategy for Clearing HBV cccDNA, but Further Validation Needed

Professor Jun Cheng: New Strategy for Clearing HBV cccDNA, but Further Validation Needed

Clinical cure of chronic hepatitis B (CHB), also known as functional cure, is achieved when patients remain HBsAg negative after stopping treatment, with or without the presence of anti-HBs, HBV DNA levels below the detection limit, and normal liver biochemical indicators. However, HBV covalently closed circular DNA (cccDNA) may still persist in the nuclei of liver cells in these patients. Therefore, clearing HBV cccDNA remains a major obstacle to achieving complete virological cure of CHB. Recently, at the 17th National Clinical Conference on Liver Diseases held in Shenyang, "Hepatology Digest" invited Professor Jun Cheng from Hebei Wutu Pharmaceutical Co., Ltd. to discuss the clearance of HBV cccDNA and other related issues.
Xinghai Forum: Professors Hong Hu and Yuntao Wei Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer

Xinghai Forum: Professors Hong Hu and Yuntao Wei Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have brought transformative breakthroughs to the clinical treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients. The combination of CDK4/6 inhibitors and endocrine therapy has become the standard regimen for HR+/HER2- locally advanced and metastatic breast cancer. In the adjuvant treatment phase for early-stage breast cancer, CDK4/6 inhibitors have also shown positive results and have been approved for indications. The 2024 ASCO conference presented multiple advancements in the adjuvant treatment of HR+/HER2- early-stage breast cancer with CDK4/6 inhibitors. At the recent 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum, Oncology Frontier invited Professor Hong Hu from Shenzhen People's Hospital, and Professor Yuntao Wei from Liaoning Cancer Hospital & Institute to elaborate on and discuss the research progress of CDK4/6 inhibitors in adjuvant therapy for HR+ early-stage breast cancer.
APACC Live Report: Dr. Rongqiu Liu from Professor Hua You’s Team Shares Research Findings and Management Strategies for HIV-Associated Malignancies

APACC Live Report: Dr. Rongqiu Liu from Professor Hua You’s Team Shares Research Findings and Management Strategies for HIV-Associated Malignancies

For HIV patients, encountering malignancies is akin to a double blow, exacerbating their already challenging condition. HIV-infected individuals commonly face opportunistic diseases such as diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). Enhancing early diagnosis and treatment of HIV-associated tumors and refining clinical management strategies are critical areas for clinical and research exploration. At the recent 9th Asia Pacific AIDS and Co-infections Conference (APACC 2024), Dr. Rongqiu Liu from Professor Hua You’s team at Children's Hospital of Chongqing Medical University presented two studies on risk prediction models for HIV-associated lymphomas and received conference funding support. "Infectious Diseases Frontier" interviewed Dr. Liu on-site to discuss her team’s research findings and management strategies for patients with HIV-associated malignancies.
Professor Houwen Lin: The Role of Clinical Pharmacy in the Diagnosis and Treatment of Major Chronic Diseases

Professor Houwen Lin: The Role of Clinical Pharmacy in the Diagnosis and Treatment of Major Chronic Diseases

With the increasing aging population in China, major chronic diseases have become the leading cause of death and the most significant disease burden for Chinese residents. As an essential means of treating chronic diseases, medications urgently require scientific, rational, and precise usage and management. At a domestic academic conference, Professor Houwen Lin from Shanghai Jiao Tong University School of Medicine, gave a remarkable academic report titled "The Role of Clinical Pharmacy in the Diagnosis and Treatment of Major Chronic Diseases." He provided a detailed introduction of how the clinical pharmacy team at Renji Hospital, driven by clinical needs, established key technologies for precise medication and new drug clinical positioning for major chronic diseases such as cardiovascular metabolism, rheumatology, and oncology. This article summarizes the report's content for the readers of Hepatology Digest.